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the LAD. The ratio of SF is higher in RCA than LCA, and not improved
even in new generation DES.
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BACKGROUND Long stenting after ﬁrst-generation drug-eluting
stents (DES) implantation was associated with adverse cardiac events.
However, it remains unclear whether long stenting after newer-gen-
eration DES implantation has an impact on clinical outcomes. Our aim
was to compare clinical outcomes of the Nobori biolimus-eluting stent
(BES) and the Xience/Promus cobalt chronium everolimus-eluting
stent (CoCr-EES) in patients with de novo long coronary artery lesions.
METHODS A total of 2272 patients with 3146 lesions undergoing BES
(1270 patients with 1751 lesions) and CoCr-EES (1002 patients with
1395 lesions) implantation between February 2010 and July 2012 were
analyzed. Of these, 1310 patients with 1528 lesions (BES, 753 patients
with 877 lesions; CoCr-EES, 557 patients with 651 lesions) had de novo
coronary artery lesions, deﬁned as total stent length 28 mm. We
assessed the rates of major adverse cardiac events (MACE), deﬁned as
a composite of cardiac death, non-fatal myocardial infarction (MI),
deﬁnite stent thrombosis, and clinically driven target lesion revas-
cularization (TLR) within 2-year.
RESULTS Baseline patient and lesion characteristics were similar be-
tween BES and EES groups. Total stent length was not signiﬁcant
different between the 2 groups (44.718.5mm vs. 46.220.6mm,
p¼0.13). The 2-year MACE rate was not signiﬁcantly different between
both groups (11.8% vs. 14.6%, p¼0.21). Cumulative incidence of car-
diac death, MI, deﬁnite stent thrombosis, and clinically driven TLR
rate were similar between the 2 groups (3.7% vs. 3.5%, p¼0.73; 1.3%
vs. 1.1%, p¼0.76; 1.0% vs. 0.7%, p¼0.61; 8.4% vs. 11.6%, p¼0.09,
respectively).CONCLUSIONS At 2-year, both BES and CoCr-EES show acceptable
clinical outcomes in patients with de novo coronary artery lesions.
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BACKGROUND Limited data are available on long-term clinical out-
comes of the second-generation drug-eluting stents (DES) compared
with the ﬁrst-generation DES in patients with coronary chronic total
occlusion (CTO) undergoing percutaneous coronary intervention
(PCI). The aim of this study is to compare the clinical outcomes of the
second-generation DES with the ﬁrst-generation DES for the treat-
ment of CTO.
METHODS Between March 2003 and February 2012, 1,006 consecutive
CTO patients who undergoing successful PCI using either ﬁrst-gen-
eration DES (n ¼ 557) or second-generation DES (n ¼ 449) were
enrolled in a multicenter, observational registry. Propensity-score
matching was also performed. The primary outcome was cardiac
death at 3-year follow-up.
RESULTS There were no signiﬁcant differences in the rate of cardiac
death (1st-generation DES versus 2nd-generation DES; 3.8% vs 2.2%;
hazard ratio [HR]: 0.70; 95% conﬁdence interval [CI]: 0.33 to 1.48; p ¼
0.70) and MACE (14.7% vs 12.5%; HR: 0.99; 95% CI: 0.70 to 1.39; p ¼
0.94). After propensity score matching, the incidence of cardiac death
(HR: 0.71; 95% CI: 0.32 to 1.57; p ¼ 0.40) and MACE (HR: 0.92; 95% CI:
0.64 to 1.32; p ¼ 0.66) were still similar in the both group. Further-
more, there were no signiﬁcant differences in the rates of cardiac
death and MACE between any different DES of sirolimus, paclitaxel,
zotarolimus, and everolimus-eluting stents.
CONCLUSIONS This study showed that the comparable effectiveness
of the second-generation DES with the ﬁrst-generation DES for
treatment of CTO at 3-year follow-up.
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